Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$27 Mln
P/E Ratio
--
P/B Ratio
1.45
Industry P/E
--
Debt to Equity
0.03
ROE
-1.57 %
ROCE
-150.99 %
Div. Yield
0 %
Book Value
0.47
EPS
-0.85
CFO
$-44.71 Mln
EBITDA
$-94.46 Mln
Net Profit
$-52.34 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cognition Therapeutics Inc (CGTX)
| -37.57 | -10.62 | -41.93 | -78.00 | -48.20 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Cognition Therapeutics Inc (CGTX)
| -61.79 | -11.90 | -66.77 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its... lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York. Read more
CEO, President & Director
Ms. Lisa Ricciardi
CEO, President & Director
Ms. Lisa Ricciardi
Headquarters
Purchase, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cognition Therapeutics Inc (CGTX) stood at $ 30 Mln as on 31-Dec-24
The share price of Cognition Therapeutics Inc (CGTX) is $0.44 (NASDAQ) as of 25-Apr-2025 16:14 EDT. Cognition Therapeutics Inc (CGTX) has given a return of -48.2% in the last 3 years.
Cognition Therapeutics Inc (CGTX) has a market capitalisation of $ 27 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cognition Therapeutics Inc (CGTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cognition Therapeutics Inc (CGTX) and enter the required number of quantities and click on buy to purchase the shares of Cognition Therapeutics Inc (CGTX).
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
The CEO & director of Ms. Lisa Ricciardi. is Cognition Therapeutics Inc (CGTX), and CFO & Sr. VP is Ms. Lisa Ricciardi.
There is no promoter pledging in Cognition Therapeutics Inc (CGTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Cognition Therapeutics Inc (CGTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-157.19
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cognition Therapeutics Inc (CGTX) was $0 Mln.
$0.00
(
